Compounds > 3,7-dihydroxy-12-oxocholanoic acid
Page last updated: 2024-11-06

3,7-dihydroxy-12-oxocholanoic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3,7-dihydroxy-12-oxocholanoic acid: RN given refers to (3alpha,5beta,7alpha)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID94235
CHEBI ID16312
SCHEMBL ID1071844
MeSH IDM0085079

Synonyms (58)

Synonym
2458-08-4
CHEBI:16312 ,
3alpha,7alpha-dihydroxy-12-oxo-5beta-cholan-24-oic acid
3,7-dihydroxy-12-oxocholanoic acid
(3alpha,5beta,7alpha)-3,7-dihydroxy-12-oxocholan-24-oic acid
3alpha,7alpha-dihydroxy-12-oxo-5beta-cholanic acid
LMST04010176
(4r)-4-[(3r,5s,7r,8r,9s,10s,13r,14s,17r)-3,7-dihydroxy-10,13-dimethyl-12-oxo-1,2,3,4,5,6,7,8,9,11,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]pentanoic acid
12-oxochenodeoxycholic acid
O0267
cholan-24-oic acid, 3,7-dihydroxy-12-oxo-, (3 alpha,5 beta,7 alpha)-
ec 219-542-6
3mke33n44o ,
einecs 219-542-6
unii-3mke33n44o
3.alpha.,7.alpha.-dihydroxy-12-oxocholic acid
12-keto-chenodeoxycholic acid
3.alpha.,7.alpha.-dihydroxy-12-oxo-5.beta.-cholanoic acid
12-oxo-3.alpha.,7.alpha.-dihydroxy-5.beta.-cholan-24-oic acid
3.alpha.,7.alpha.-dihydroxy-12-keto-5.beta.-cholanic acid
3.alpha.,7.alpha.-dihydroxy-12-ketocholanic acid
3.alpha.,7.alpha.-dihydroxy-12-oxo-5.beta.-cholan-24-oic acid
3.alpha.,7.alpha.-dihydroxy-12-oxo-5.beta.-cholanic acid
12-ketochenodeoxycholic acid
5.beta.-cholanic acid, 3.alpha.,7.alpha.-dihydroxy-12-oxo-
5.beta.-cholanic acid-3.alpha.,7.alpha.-diol-12-one
5.beta.-cholan-24-oic acid, 3.alpha.,7.alpha.-dihydroxy-12-oxo-
3.alpha.,7.alpha.-dihydroxy-12-ketocholic acid
SCHEMBL1071844
AKOS024436507
12-keto-cdca
12-keto-3a,7a-dihydroxy-5b-cholanate
3a,7a-dihydroxy-12-ketocholic acid
3a,7a-dihydroxy-12-ketocholate
3a,7a-dihydroxy-12-oxocholate
3a,7a-dihydroxy-12-ketocholanate
3a,7a-dihydroxy-12-oxo-5b-cholan-24-oate
12-ketochenodeoxycholate
3a,7a-dihydroxy-12-oxo-5b-cholan-24-oic acid
3a,7a-dihydroxy-12-oxo-5b-cholanate
12-oxo-3a,7a-dihydroxy-5b-cholan-24-oate
3a,7a-dihydroxy-12-oxocholic acid
3a,7a-dihydroxy-12-oxo-5b-cholanoic acid
12-oxochenodeoxycholate
12-keto-3a,7a-dihydroxy-5b-cholanic acid
3a,7a-dihydroxy-12-oxo-5b-cholanic acid
5b-cholanic acid-3a,7a-diol-12-one
3a,7a-dihydroxy-12-oxo-5b-cholanoate
3a,7a-dihydroxy-12-keto-5b-cholanic acid
3,7-dihydroxy-12-oxocholanoate
3a,7a-dihydroxy-12-ketocholanic acid
3a,7a-dihydroxy-12-keto-5b-cholanate
12-oxo-3a,7a-dihydroxy-5b-cholan-24-oic acid
(3a,5b,7a)-3,7-dihydroxy-12-oxo-cholan-24-oate
12-keto-chenodeoxycholate
Q27101844
5beta-cholanic acid-3alpha,7alpha-diol-12-one
DTXSID601334921

Research Excerpts

Compound-Compound Interactions

ExcerptReferenceRelevance
" The decrease in MKC bioavailability, when administered with gliclazide, caused by probiotic treatment in healthy but not diabetic rats suggests that probiotic treatment induced MKC metabolism or impaired its absorption, only in healthy animals."( Probiotics decreased the bioavailability of the bile acid analog, monoketocholic acid, when coadministered with gliclazide, in healthy but not diabetic rats.
Al-Salami, H; Butt, G; Golocorbin-Kon, S; Mikov, M; Tucker, I, 2012)		0.38

Bioavailability

ExcerptReferenceRelevance
" When coadministered with gliclazide, the bioavailability of MKC was reduced in healthy rats treated with probiotics but remained the same in diabetic pretreated rats."( Probiotics decreased the bioavailability of the bile acid analog, monoketocholic acid, when coadministered with gliclazide, in healthy but not diabetic rats.
Al-Salami, H; Butt, G; Golocorbin-Kon, S; Mikov, M; Tucker, I, 2012)		0.38
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
oxo-5beta-cholanic acid
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (33.33)18.7374
1990's0 (0.00)18.2507
2000's3 (20.00)29.6817
2010's5 (33.33)24.3611
2020's2 (13.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.64

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.64 (24.57)
Research Supply Index3.00 (2.92)
Research Growth Index4.64 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.64)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other19 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
acetone
methyl ketone : A ketone of formula RC(=O)CH3 (R =/= H).		2.0310ketone body;
methyl ketone;
propanones;
volatile organic compound		EC 3.5.1.4 (amidase) inhibitor;
human metabolite;
polar aprotic solvent
glycine
[no description available]		1.9510alpha-amino acid;
amino acid zwitterion;
proteinogenic amino acid;
serine family amino acid		EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor;
fundamental metabolite;
hepatoprotective agent;
micronutrient;
neurotransmitter;
NMDA receptor agonist;
nutraceutical
taurine
[no description available]		1.9510amino sulfonic acid;
zwitterion		antioxidant;
Escherichia coli metabolite;
glycine receptor agonist;
human metabolite;
mouse metabolite;
nutrient;
radical scavenger;
Saccharomyces cerevisiae metabolite
urea
pseudourea: clinical use; structure. isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.		2.0510isourea;
monocarboxylic acid amide;
one-carbon compound		Daphnia magna metabolite;
Escherichia coli metabolite;
fertilizer;
flour treatment agent;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
erythrosine
Fluoresceins: A family of spiro(isobenzofuran-1(3H),9'-(9H)xanthen)-3-one derivatives. These are used as dyes, as indicators for various metals, and as fluorescent labels in immunoassays.		2.0710
gliclazide
Gliclazide: An oral sulfonylurea hypoglycemic agent which stimulates insulin secretion.		2.0710N-sulfonylureahypoglycemic agent;
insulin secretagogue;
radical scavenger
nitrazepam
Nitrazepam: A benzodiazepine derivative used as an anticonvulsant and hypnotic.. nitrazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one which is substituted at positions 5 and 7 by phenyl and nitro groups, respectively. It is used as a hypnotic for the short-term management of insomnia and for the treatment of epileptic spasms in infants (West's syndrome).		2.05101,4-benzodiazepinone;
C-nitro compound		anticonvulsant;
antispasmodic drug;
drug metabolite;
GABA modulator;
sedative
alloxan
Alloxan: Acidic compound formed by oxidation of URIC ACID. It is isolated as an efflorescent crystalline hydrate.. alloxan : A member of the class of pyrimidones, the structure of which is that of perhydropyrimidine substituted at C-2, -4, -5 and -6 by oxo groups.		2.3110pyrimidonehyperglycemic agent;
metabolite
dehydrocholic acid
Dehydrocholic Acid: A semisynthetic bile acid made from cholic acid. It is used as a cholagogue, hydrocholeretic, diuretic, and as a diagnostic aid.. 3,7,12-trioxo-5beta-cholanic acid : An oxo-5beta-cholanic acid in which three oxo substituents are located at positions 3, 7 and 12 on the cholanic acid skeleton.		2.372012-oxo steroid;
3-oxo-5beta-steroid;
7-oxo steroid;
oxo-5beta-cholanic acid		gastrointestinal drug
lithocholic acid
Lithocholic Acid: A bile acid formed from chenodeoxycholate by bacterial action, usually conjugated with glycine or taurine. It acts as a detergent to solubilize fats for absorption and is itself absorbed. It is used as cholagogue and choleretic.. lithocholic acid : A monohydroxy-5beta-cholanic acid with a alpha-hydroxy substituent at position 3. It is a bile acid obtained from chenodeoxycholic acid by bacterial action.. lithocholate : A bile acid anion that is the conjugate base of lithocholic acid.		2.3620bile acid;
C24-steroid;
monohydroxy-5beta-cholanic acid		geroprotector;
human metabolite;
mouse metabolite
chenodeoxycholic acid
Chenodeoxycholic Acid: A bile acid, usually conjugated with either glycine or taurine. It acts as a detergent to solubilize fats for intestinal absorption and is reabsorbed by the small intestine. It is used as cholagogue, a choleretic laxative, and to prevent or dissolve gallstones.. chenodeoxycholic acid : A dihydroxy-5beta-cholanic acid that is (5beta)-cholan-24-oic acid substituted by hydroxy groups at positions 3 and 7 respectively.. chenodeoxycholate : Conjugate base of chenodeoxycholic acid; major species at pH 7.3.		4.09150bile acid;
C24-steroid;
dihydroxy-5beta-cholanic acid		human metabolite;
mouse metabolite
rhodamine 6g
rhodamine 6G: RN given refers to HCl		2.0510
ursodeoxycholic acid
Ursodeoxycholic Acid: An epimer of chenodeoxycholic acid. It is a mammalian bile acid found first in the bear and is apparently either a precursor or a product of chenodeoxycholate. Its administration changes the composition of bile and may dissolve gallstones. It is used as a cholagogue and choleretic.. ursodeoxycholic acid : A bile acid found in the bile of bears (Ursidae) as a conjugate with taurine. Used therapeutically, it prevents the synthesis and absorption of cholesterol and can lead to the dissolution of gallstones.. ursodeoxycholate : A bile acid anion that is the conjugate base of ursodeoxycholic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.		1.9510bile acid;
C24-steroid;
dihydroxy-5beta-cholanic acid		human metabolite;
mouse metabolite
6-carboxyfluorescein
6-carboxyfluorescein: originally sold as 6-carboxyfluorescein, but commercial product is a mixture of two isomers; correct name is 5(6)-carboxyfluorescein		2.0710monocarboxylic acid
methotrexate
[no description available]		2.0510dicarboxylic acid;
monocarboxylic acid amide;
pteridines		abortifacient;
antimetabolite;
antineoplastic agent;
antirheumatic drug;
dermatologic drug;
DNA synthesis inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
immunosuppressive agent
7-ketodeoxycholic acid
7-ketodeoxycholic acid: RN given refers to (3 alpha,5 beta,12 alpha)-isomer		2.36207-oxo steroid;
oxo-5beta-cholanic acid
cholic acid
Cholic Acid: A major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion.. cholic acid : A bile acid that is 5beta-cholan-24-oic acid bearing three alpha-hydroxy substituents at position 3, 7 and 12.		3.125012alpha-hydroxy steroid;
3alpha-hydroxy steroid;
7alpha-hydroxy steroid;
bile acid;
C24-steroid;
trihydroxy-5beta-cholanic acid		human metabolite;
mouse metabolite
deoxycholic acid
Deoxycholic Acid: A bile acid formed by bacterial action from cholate. It is usually conjugated with glycine or taurine. Deoxycholic acid acts as a detergent to solubilize fats for intestinal absorption, is reabsorbed itself, and is used as a choleretic and detergent.. deoxycholic acid : A bile acid that is 5beta-cholan-24-oic acid substituted by hydroxy groups at positions 3 and 12 respectively.		2.9140bile acid;
C24-steroid;
dihydroxy-5beta-cholanic acid		human blood serum metabolite
7-ketolithocholic acid
7-ketolithocholic acid: RN given refers to (3alpha,5beta)-isomer. 7-oxolithocholic acid : A bile acid that is lithocholic acid carrying an additional oxo substituent at position 7.		1.95103alpha-hydroxy steroid;
bile acid;
monohydroxy-5beta-cholanic acid;
oxo-5beta-cholanic acid		human metabolite
nadp
[no description available]		2.3920
12-ketolithocholic acid
12-ketolithocholic acid: RN given refers to (3alpha,5beta)-isomer		1.9610bile acid
rhodamine 123
Rhodamine 123: A fluorescent probe with low toxicity which is a potent substrate for ATP BINDING CASSETTE TRANSPORTER, SUBFAMILY B, MEMBER 1 and the bacterial multidrug efflux transporter. It is used to assess mitochondrial bioenergetics in living cells and to measure the efflux activity of ATP BINDING CASSETTE TRANSPORTER, SUBFAMILY B, MEMBER 1 in both normal and malignant cells. (Leukemia 1997;11(7):1124-30). rhodamine 123(1+) : A cationic fluorescent dye derived from 9-phenylxanthene.		2.0710organic cation;
xanthene dye		fluorochrome
morphine-6-glucuronide
morphine-6-glucuronide: RN given refers to (5alpha,6alpha)-isomer		2.0810morphinane alkaloid
ConditionIndicatedRelationship StrengthStudiesTrials
Alloxan Diabetes
[description not available]		02.5420
Pain, Chronic
[description not available]		02.3110
Adjuvant Arthritis
[description not available]		02.3110
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.3110
Chronic Pain
Aching sensation that persists for more than a few months. It may or may not be associated with trauma or disease, and may persist after the initial injury has healed. Its localization, character, and timing are more vague than with acute pain.		02.3110
Autoimmune Diabetes
[description not available]		02.0710
Diabetes Mellitus, Type 1
A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.		02.0710
Esophageal Varices
[description not available]		01.9610
Encephalopathy, Hepatic
[description not available]		01.9610
Cirrhosis, Liver
[description not available]		01.9610
Ascites
Accumulation or retention of free fluid within the peritoneal cavity.		01.9610
Esophageal and Gastric Varices
Dilated blood vessels in the ESOPHAGUS or GASTRIC FUNDUS that shunt blood from the portal circulation (PORTAL SYSTEM) to the systemic venous circulation. Often they are observed in individuals with portal hypertension (HYPERTENSION, PORTAL).		01.9610
Hepatic Encephalopathy
A syndrome characterized by central nervous system dysfunction in association with LIVER FAILURE, including portal-systemic shunts. Clinical features include lethargy and CONFUSION (frequently progressing to COMA); ASTERIXIS; NYSTAGMUS, PATHOLOGIC; brisk oculovestibular reflexes; decorticate and decerebrate posturing; MUSCLE SPASTICITY; and bilateral extensor plantar reflexes (see REFLEX, BABINSKI). ELECTROENCEPHALOGRAPHY may demonstrate triphasic waves. (From Adams et al., Principles of Neurology, 6th ed, pp1117-20; Plum & Posner, Diagnosis of Stupor and Coma, 3rd ed, p222-5)		01.9610
Liver Cirrhosis
Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.		01.9610
Common Bile Duct Neoplasms
Tumor or cancer of the COMMON BILE DUCT including the AMPULLA OF VATER and the SPHINCTER OF ODDI.		01.9710
Bile Duct Obstruction, Intrahepatic
[description not available]		01.9610
Symptom Cluster
[description not available]		01.9610
Cholestasis, Intrahepatic
Impairment of bile flow due to injury to the HEPATOCYTES; BILE CANALICULI; or the intrahepatic bile ducts (BILE DUCTS, INTRAHEPATIC).		01.9610
Syndrome
A characteristic symptom complex.		01.9610